Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Prostate Cancer

Free Subscription Articles published in Int J Urol Retrieve available abstracts of 126 articles: HTML format

Single Articles

October 2025
1. SUZUKI K, Khan N, Taguchi T, Hattori K, et al
   Androgen Receptor Signaling Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer in Japan: The ARASHI Study.
   Int J Urol. 2025 Oct 3. doi: 10.1111/iju.70235.
   PubMed     Abstract available
   
   
   
2. SASAKI T, Higashi S, Nishikawa T, Sugino Y, et al
   Short-Term Longitudinal Changes in Quality of Life Among Japanese Patients With Prostate Cancer After Single-Port Robot-Assisted Radical Prostatectomy: A Preliminary Prospective Study.
   Int J Urol. 2025 Oct 1. doi: 10.1111/iju.70251.
   PubMed    
   
   
   
3. YASUDA Y, Yoshida S, Matsubara D, Takahara T, et al
   Outcomes and Safety Profile of Repeated Progressive Site-Directed Therapy for Patients With Oligometastatic Castration-Resistant Prostate Cancer.
   Int J Urol. 2025 Oct 1. doi: 10.1111/iju.70253.
   PubMed    
   
   
   
4. ESCANDE R, Jaouen T, Gonindard-Melodelima C, Crouzet S, et al
   External Validation on a Japanese Cohort of a Computer-Aided Diagnosis System Aimed at Characterizing ISUP >/= 2 Prostate Cancers at Multiparametric MRI.
   Int J Urol. 2025;32:1440-1448.
   PubMed     Abstract available
   
   
   September 2025
5. DENIZ ME, Gur G, Kayra MV, Hasbay B, et al
   PSMA PET/CT and Multiparametric MRI in Assessing Local Extension and Lymph Node Metastasis in Prostate Cancer.
   Int J Urol. 2025 Sep 24. doi: 10.1111/iju.70239.
   PubMed     Abstract available
   
   
   
6. MIYOSHI Y, Uemura H, Ohta J, Kobayashi K, et al
   Prognostic Value of BONENAVI Computer-Aided Diagnosis System Bone Scans as an Imaging Biomarker for Bone-Metastatic Castration-Sensitive Prostate Cancer: An Investigator-Initiated, Multicenter, Prospective Observational Study.
   Int J Urol. 2025 Sep 23. doi: 10.1111/iju.70214.
   PubMed     Abstract available
   
   
   
7. HATANO K
   Editorial Comment on "Nomogram for Predicting the Survival Outcome of Cabazitaxel Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer: A Multi-Institutional Analysis".
   Int J Urol. 2025 Sep 17. doi: 10.1111/iju.70236.
   PubMed    
   
   
   
8. NAKAJIMA Y, Hashimoto K, Shindo T, Kobayashi K, et al
   Prostate-Specific Antigen Dynamics and Bone Predominance as Predictors of Efficacy in Radium-223 Treatment for Castration-Resistant Prostate Cancer.
   Int J Urol. 2025 Sep 16. doi: 10.1111/iju.70229.
   PubMed    
   
   
   
9. SUZUKI K, Hirata J, Ueki H, Wakita N, et al
   Nomogram for Predicting the Survival Outcome of Cabazitaxel Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer: A Multi-Institutional Analysis.
   Int J Urol. 2025 Sep 3. doi: 10.1111/iju.70219.
   PubMed     Abstract available
   
   
   
10. MATSUYAMA N, Suzuki K, Tobe T, Ueki H, et al
    Time to Oligoprogression From the Initiation of the Most Recent Systemic Treatment Is Associated With the Outcome of Progressive Site-Directed Therapy for Castration-Resistant Prostate Cancer.
    Int J Urol. 2025 Sep 2. doi: 10.1111/iju.70217.
    PubMed     Abstract available
    
    
    
11. KAWASE M
    Editorial Comment Regarding "Shifts in Diagnostic Approaches for Prostate Cancer: Impact of MRI-Informed Biopsies on Low-Risk Cancer Detection".
    Int J Urol. 2025 Sep 1. doi: 10.1111/iju.70218.
    PubMed    
    
    
    August 2025
12. ARAI S
    Editorial Comment on Efficacy of Docetaxel Addition to Next-Generation Androgen Receptor-Axis-Targeted Therapies and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Tumor Volume-Specific Analysis.
    Int J Urol. 2025 Aug 21. doi: 10.1111/iju.70208.
    PubMed    
    
    
    
13. IWAMOTO H, Hori T, Inaba T, Nakagawa R, et al
    Prognostic Impact of Time to Castration Resistance on Overall Survival in Patients With Metastatic Castration-Sensitive Prostate Cancer.
    Int J Urol. 2025 Aug 19. doi: 10.1111/iju.70197.
    PubMed     Abstract available
    
    
    
14. SHIMOMURA T
    Editorial Comment to "Preliminary Report on the Efficacy and Safety of Triplet Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer: YUSHIMA Study".
    Int J Urol. 2025 Aug 19. doi: 10.1111/iju.70185.
    PubMed    
    
    
    
15. YAMAMOTO Y, Fujimoto S, Hashimoto M, Minami T, et al
    Comparison of Oncological Outcomes of Conventional Androgen Deprivation Therapy (ADT) and ADT Plus Androgen Receptor Signaling Inhibitor in Older Patients With Metastatic Castration-Sensitive Prostate Cancer.
    Int J Urol. 2025 Aug 14. doi: 10.1111/iju.70202.
    PubMed     Abstract available
    
    
    
16. YASUDA Y, Wang Z, Yoshida S, Chen W, et al
    Indirect Comparison of PROpel and TALAPRO-2 Trials Using the Shiny Method: A Comparative Analysis in Metastatic Castration-Resistant Prostate Cancer.
    Int J Urol. 2025 Aug 12. doi: 10.1111/iju.70194.
    PubMed    
    
    
    
17. ARAI S
    Editorial Comment on Preliminary Report on the Efficacy and Safety of Triplet Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer: YUSHIMA Study.
    Int J Urol. 2025 Aug 10. doi: 10.1111/iju.70201.
    PubMed    
    
    
    
18. TOHI Y, Kato T, Fujiwara K, Harada S, et al
    Shifts in Diagnostic Approaches for Prostate Cancer: Impact of MRI-Informed Biopsies on Low-Risk Cancer Detection.
    Int J Urol. 2025 Aug 3. doi: 10.1111/iju.70193.
    PubMed     Abstract available
    
    
    
19. SOMOTO T, Utsumi T, Ishitsuka N, Noro T, et al
    Clinical Predictors of Fluoroquinolone-Resistant Escherichia coli in Transrectal Ultrasound-Guided Prostate Biopsy: Insights for Tailored Prophylaxis.
    Int J Urol. 2025;32:982-989.
    PubMed     Abstract available
    
    
    July 2025
20. HIRATA H
    Editorial Comment on "Frontiers of Ultrasound Technology in Prostate Cancer Treatment".
    Int J Urol. 2025 Jul 19. doi: 10.1111/iju.70183.
    PubMed    
    
    
    
21. MITSUI Y, Nakajima K
    Editorial Comment on "Risk Model for Lymph Node-Positive Prostate Cancer After Radical Prostatectomy".
    Int J Urol. 2025 Jul 1. doi: 10.1111/iju.70166.
    PubMed    
    
    
    June 2025
22. SHOJI S, Takahashi K, Naruse J, Kawamura Y, et al
    Frontiers of Ultrasound Technology in Prostate Cancer Treatment.
    Int J Urol. 2025 Jun 22. doi: 10.1111/iju.70160.
    PubMed     Abstract available
    
    
    
23. TASHIRO K, Mori K, Shiota M, Fukuokaya W, et al
    Risk Model for Lymph Node-Positive Prostate Cancer After Radical Prostatectomy.
    Int J Urol. 2025 Jun 16. doi: 10.1111/iju.70149.
    PubMed     Abstract available
    
    
    
24. YASUDA Y, Numao N, Matsumoto S, Tamiya T, et al
    Preliminary Report on the Efficacy and Safety of Triplet Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer: YUSHIMA Study.
    Int J Urol. 2025 Jun 16. doi: 10.1111/iju.70154.
    PubMed     Abstract available
    
    
    
25. WATANABE R
    Editorial Comment to "VIRMA Accelerates the Tumorigenesis of Prostate Cancer via Regulating the m6A Modification of NSMCE2 to Eliminate the Generation of Reactive Oxygen Species".
    Int J Urol. 2025 Jun 16. doi: 10.1111/iju.70150.
    PubMed    
    
    
    
26. OKUDA Y, Kato T, Ishizuya Y, Hayashi T, et al
    PARP Inhibitors in Genitourinary Cancer: A New Paradigm Beyond Prostate Cancer.
    Int J Urol. 2025 Jun 9. doi: 10.1111/iju.70100.
    PubMed     Abstract available
    
    
    
27. PATTOU M, Neuzillet Y, Ghoneim T, Bosset PO, et al
    Evaluating the Safety of Delaying Surgery Beyond 9 Months in Localized Prostate Cancer Patients: Results From a Prospective Study With Propensity Score Matching.
    Int J Urol. 2025 Jun 4. doi: 10.1111/iju.70142.
    PubMed     Abstract available
    
    
    
28. MA J, Qu X
    VIRMA Accelerates the Tumorigenesis of Prostate Cancer via Regulating the m(6)A Modification of NSMCE2 to Eliminate the Generation of Reactive Oxygen Species.
    Int J Urol. 2025 Jun 3. doi: 10.1111/iju.70140.
    PubMed     Abstract available
    
    
    
29. FALKENBACH F, Penaranda NR, Longoni M, Marmiroli A, et al
    The Effect of Chronic Kidney Disease on Adverse In-Hospital Outcomes at Radical Prostatectomy.
    Int J Urol. 2025;32:710-717.
    PubMed     Abstract available
    
    
    
30. KIMURA Y, Honda M, Yamane H, Shimizu R, et al
    Outcomes in Health-Related Quality of Life and Impact of Urinary Incontinence on Health-Related Quality of Life 7 Years After Robot-Assisted Radical Prostatectomy.
    Int J Urol. 2025;32:664-671.
    PubMed     Abstract available
    
    
    May 2025
31. ZHAO X, Sakamoto S, Yamada Y, Sato K, et al
    The Role of Serum Testosterone in the Pathogenesis and Treatment of Prostate Cancer: A Review Based on the Clinical Evidence.
    Int J Urol. 2025 May 23. doi: 10.1111/iju.70125.
    PubMed     Abstract available
    
    
    
32. REIKE MJ, Tully KH, Schulmeier M, Reicherz A, et al
    Functional Outcomes in Patients With Prostate Cancer Undergoing Frozen Section Guided Radical Prostatectomy.
    Int J Urol. 2025 May 20. doi: 10.1111/iju.70115.
    PubMed     Abstract available
    
    
    
33. HATANO K
    Editorial Comment on "Is Docetaxel Essential for Darolutamide-Based Metastatic Hormone-Sensitive Prostate Cancer Therapy?".
    Int J Urol. 2025 May 7. doi: 10.1111/iju.70093.
    PubMed    
    
    
    April 2025
34. ROLDAN-TESTILLANO R, Sanchez-Salas R
    Editorial Comment on "Active Surveillance in Prostate Cancer With Intermediate-Risk Features: The PRIAS-JAPAN Study".
    Int J Urol. 2025 Apr 25. doi: 10.1111/iju.70083.
    PubMed    
    
    
    
35. NORO T, Utsumi T, Ishitsuka N, Suzuki Y, et al
    Impact of the COVID-19 Pandemic on Prostate Cancer: Perturbations in Screening and Diagnostic Patterns.
    Int J Urol. 2025 Apr 24. doi: 10.1111/iju.70085.
    PubMed     Abstract available
    
    
    
36. CHEN W, Yoshida S, Fujii Y
    Is Docetaxel Essential for Darolutamide-Based Metastatic Hormone-Sensitive Prostate Cancer Therapy?
    Int J Urol. 2025 Apr 17. doi: 10.1111/iju.70072.
    PubMed    
    
    
    
37. BLAS L, Shiota M, Kato T, Matsumoto R, et al
    Active Surveillance in Prostate Cancer With Intermediate-Risk Features: The PRIAS-JAPAN Study.
    Int J Urol. 2025 Apr 7. doi: 10.1111/iju.70063.
    PubMed     Abstract available
    
    
    
38. DLAMINI KCS, Coetzee LJ, Mathabe K
    South African single surgeon experience: Comparison of oncological outcomes, robot-assisted radical prostatectomy versus open perineal radical prostatectomy.
    Int J Urol. 2025;32:423-426.
    PubMed     Abstract available
    
    
    
39. FUNAJIMA K, Naito S, Fukai A, Narisawa T, et al
    Urinary continence outcomes after robot-assisted laparoscopic radical prostatectomy: Significance of anterior reconstruction.
    Int J Urol. 2025;32:355-360.
    PubMed     Abstract available
    
    
    
40. KAWAMURA N, Nakayama M, Hayashi T, Nagahara A, et al
    Risk assessment of late biochemical recurrence after radical prostatectomy: Usefulness of ultra-sensitive prostate-specific antigen measurement.
    Int J Urol. 2025;32:380-386.
    PubMed     Abstract available
    
    
    March 2025
41. YAMAMOTO Y
    Editorial Comments to "Overuse of Imaging in Prostate Cancer Staging".
    Int J Urol. 2025 Mar 24. doi: 10.1111/iju.70021.
    PubMed    
    
    
    
42. SEKINE Y, Fujizuka Y, Nakazawa S, Tsuji Y, et al
    Utility of Combining Prostate Health Index and Magnetic Resonance Imaging for the Diagnosis of Prostate Cancer.
    Int J Urol. 2025 Mar 17. doi: 10.1111/iju.70024.
    PubMed     Abstract available
    
    
    
43. ONISHI K, Nakai Y, Tachibana A, Nishimura N, et al
    Testosterone Recovery and Quality of Life of Japanese Patients After Short-Term Neoadjuvant Androgen Deprivation Therapy With Low-Dose-Rate Brachytherapy for Prostate Cancer.
    Int J Urol. 2025 Mar 5. doi: 10.1111/iju.70018.
    PubMed     Abstract available
    
    
    
44. SEKITO T, Sadahira T
    Editorial Comment on Testosterone Recovery and Quality of Life of Japanese Patients After Short-Term Neoadjuvant Androgen Deprivation Therapy With Low-Dose Rate Brachytherapy for Prostate Cancer.
    Int J Urol. 2025 Mar 5. doi: 10.1111/iju.70035.
    PubMed    
    
    
    
45. GUNGE N, Fukuhara Y, Matsuoka W, Fumihiro Y, et al
    Effect of ICG fluorescence-assisted new nerve-sparing of robot-assisted radical prostatectomy on lower urinary tract symptoms.
    Int J Urol. 2025;32:285-292.
    PubMed     Abstract available
    
    
    
46. MITSUI M, Sadahira T, Nagasaki N, Maruyama Y, et al
    Postoperative infections after robotic-assisted radical prostatectomy in a single large institution: Effect of type and duration of prophylactic antibiotic administration.
    Int J Urol. 2025;32:258-263.
    PubMed     Abstract available
    
    
    February 2025
47. MATSUOKA Y
    Editorial Comment to "Combining Percentage Prostate-Specific Antigen Reduction and Multiparametric Magnetic Resonance Imaging to Reduce Unnecessary Biopsy After Focal Therapy With High-Intensity Focused Ultrasound for Prostate Cancer".
    Int J Urol. 2025 Feb 27. doi: 10.1111/iju.70031.
    PubMed    
    
    
    
48. SUZUKI K, Matsuyama H, Matsubara N, Kazama H, et al
    Current Evidence on Cabazitaxel for Prostate Cancer Therapy: A Narrative Review.
    Int J Urol. 2025 Feb 25. doi: 10.1111/iju.70019.
    PubMed     Abstract available
    
    
    
49. URABE F, Kimura S
    Considerations on the Optimal Imaging for Prostate Cancer Diagnosis.
    Int J Urol. 2025 Feb 19. doi: 10.1111/iju.70016.
    PubMed    
    
    
    
50. HSIEH PF, Naruse J, Yuzuriha S, Umemoto T, et al
    Combining Percentage Prostate-Specific Antigen Reduction and Multiparametric Magnetic Resonance Imaging to Reduce Unnecessary Biopsy After Focal Therapy With High-Intensity Focused Ultrasound for Prostate Cancer.
    Int J Urol. 2025 Feb 19. doi: 10.1111/iju.70013.
    PubMed     Abstract available
    
    
    
51. IWAMOTO H, Izumi K, Mizokami A
    Editorial Comment on the Overuse of Imaging in Prostate Cancer Staging.
    Int J Urol. 2025 Feb 17. doi: 10.1111/iju.70015.
    PubMed    
    
    
    
52. TOHI Y, Kato T, Kohashiguchi K, Kaji A, et al
    Overuse of imaging in prostate cancer staging.
    Int J Urol. 2025 Feb 3. doi: 10.1111/iju.70003.
    PubMed     Abstract available
    
    
    
53. HIROSE K, Nakanishi Y, Ogasawara RA, Imasato N, et al
    Risk factors for rectal wall infiltration in hydrogel spacer placement: Influence of biopsy approach.
    Int J Urol. 2025;32:183-189.
    PubMed     Abstract available
    
    
    
54. MINAMI T, Fujimoto S, Fujita K
    Iodine-125 low-dose rate prostate brachytherapy.
    Int J Urol. 2025;32:130-137.
    PubMed     Abstract available
    
    
    January 2025
55. ARAI S
    Editorial Comment on "Changes in the treatment landscape of metastatic hormone-sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: A multicenter study".
    Int J Urol. 2025 Jan 21. doi: 10.1111/iju.15682.
    PubMed    
    
    
    
56. WASHINO S, Saito K, Yazaki K, Miyagawa T, et al
    A novel anterior approach toward robotic radical prostatectomy is associated with earlier continence recovery than the conventional approach.
    Int J Urol. 2025;32:80-87.
    PubMed     Abstract available
    
    
    
57. KOBAYASHI K, Nofuji S, Okabe K, Yorozuya W, et al
    How do Japanese patients really feel about losing potency after radical prostatectomy? (MAJI study).
    Int J Urol. 2025;32:69-72.
    PubMed     Abstract available
    
    
    
58. TEISHIMA J, Wakita N, Bando Y, Okamura Y, et al
    Effects of modifying hinotori surgical robot system on perioperative outcome of robot-assisted radical prostatectomy.
    Int J Urol. 2025;32:45-50.
    PubMed     Abstract available
    
    
    December 2024
59. CHEN W, Yoshida S, Miura N, Fukuda S, et al
    Efficacy of docetaxel addition to next-generation androgen receptor-axis-targeted therapies and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: A tumor volume-specific analysis.
    Int J Urol. 2024 Dec 20. doi: 10.1111/iju.15657.
    PubMed     Abstract available
    
    
    
60. KUMAR V, Jena D, Zahiruddin QS, Roopashree R, et al
    Prostate cancer burden in South Asia: A systematic analysis of global burden of disease data (1990-2021).
    Int J Urol. 2024 Dec 13. doi: 10.1111/iju.15641.
    PubMed     Abstract available
    
    
    
61. SUZUKI H, Akamatsu S, Shiota M, Kakiuchi H, et al
    Triplet therapy for metastatic castration-sensitive prostate cancer: Rationale and clinical evidence.
    Int J Urol. 2024 Dec 9. doi: 10.1111/iju.15647.
    PubMed     Abstract available
    
    
    
62. YE DW, Uemura H, Chung BH, Suzuki H, et al
    Prostate-specific antigen kinetics in Asian patients with metastatic castration-sensitive prostate cancer treated with apalutamide in the TITAN trial: A post hoc analysis.
    Int J Urol. 2024 Dec 9. doi: 10.1111/iju.15615.
    PubMed     Abstract available
    
    
    
63. MORIZANE S, Miki J, Shimbo M, Kanno T, et al
    Japanese expert consensus on the standardization of robot-assisted pelvic lymph node dissection in urological surgery: Extent of pelvic lymph node and surgical technique.
    Int J Urol. 2024;31:1300-1310.
    PubMed     Abstract available
    
    
    November 2024
64. HAKOZAKI Y, Yamada Y, Fujimura T, Kimura N, et al
    Novel clipping procedure for preventing post-operative inguinal hernia in robot-assisted radical prostatectomy.
    Int J Urol. 2024;31:1241-1247.
    PubMed     Abstract available
    
    
    October 2024
65. OBINATA D, Yamada Y, Sumiyoshi T, Tanegashima T, et al
    Recent advances in basic research on prostate cancer: Where we are heading?
    Int J Urol. 2024 Oct 30. doi: 10.1111/iju.15628.
    PubMed     Abstract available
    
    
    
66. SHIOTA M
    Editorial Comment to Loss of phosphatase and tensin homolog expression in castration-sensitive prostate cancer predicts outcomes in men after prostatectomy.
    Int J Urol. 2024 Oct 15. doi: 10.1111/iju.15607.
    PubMed    
    
    
    
67. SATO M, Osawa T, Nishioka K, Miyazaki T, et al
    Decision regret after curative treatment and its association with the decision-making process and quality of life for prostate cancer patients.
    Int J Urol. 2024 Oct 9. doi: 10.1111/iju.15602.
    PubMed     Abstract available
    
    
    
68. YANAI Y, Mikami S, Yasumizu Y, Takeda T, et al
    Loss of phosphatase and tensin homolog expression castration-sensitive prostate cancer predicts outcomes in men after prostatectomy.
    Int J Urol. 2024 Oct 1. doi: 10.1111/iju.15592.
    PubMed     Abstract available
    
    
    
69. KOHADA Y, Kitano H, Tasaka R, Miyamoto S, et al
    Clinical characteristics and predictors of long-term postoperative urinary incontinence in patients treated with robot-assisted radical prostatectomy: A propensity-matched analysis.
    Int J Urol. 2024;31:1145-1152.
    PubMed     Abstract available
    
    
    September 2024
70. MITSUI Y, Nakajima K
    Editorial Comment to "Causal relationship between folic acid and prostate cancer risk: Insights from Mendelian randomization analysis".
    Int J Urol. 2024 Sep 26. doi: 10.1111/iju.15582.
    PubMed    
    
    
    
71. GUO X, Zhang F, Hao G
    Causal relationship between folic acid and prostate cancer risk: Insights from Mendelian randomization analysis.
    Int J Urol. 2024 Sep 22. doi: 10.1111/iju.15565.
    PubMed     Abstract available
    
    
    
72. SHIMADA K, Fujiwara M, Hirahara D, Takaya E, et al
    Monitoring prostate cancer after low-dose-rate hemigland brachytherapy with delta-radiomics of diffusion-weighted magnetic resonance imaging.
    Int J Urol. 2024 Sep 11. doi: 10.1111/iju.15581.
    PubMed    
    
    
    
73. KAMBE T, Yamasaki T, Yamamoto A, Nagoshi A, et al
    Dose compliance of estramustine phosphate in neoadjuvant chemohormonal therapy combined with degarelix acetate predicts the biochemical recurrence in patients with very high-risk prostate cancer who underwent robot-assisted radical prostatectomy.
    Int J Urol. 2024 Sep 10. doi: 10.1111/iju.15579.
    PubMed     Abstract available
    
    
    
74. KATO T, Tohi Y, Okazoe H, Taoka R, et al
    How widespread is active surveillance of early-stage prostate cancer in Japan? Multicenter questionnaire survey on the status of active surveillance of early-stage prostate cancer in Japan.
    Int J Urol. 2024 Sep 4. doi: 10.1111/iju.15573.
    PubMed    
    
    
    
75. MORITA M, Hiramatsu A, Nishimura K, Yanagida W, et al
    Radiation proctitis after iodine-125 low-dose-rate prostate brachytherapy utilizing SpaceOAR hydrogel.
    Int J Urol. 2024;31:1001-1008.
    PubMed     Abstract available
    
    
    
76. COLAKOGLU Y, Eksi M, Ozlu DN, Simsek A, et al
    Comparison of oncological and functional results of robotic and open perineal radical prostatectomy.
    Int J Urol. 2024;31:994-1000.
    PubMed     Abstract available
    
    
    August 2024
77. MATSUOKA Y
    Editorial Comment to "Can the Briganti 2019 nomogram be modified to predict lymph node metastasis risk in patients with prostate cancer detected with in-bore biopsy?".
    Int J Urol. 2024 Aug 24. doi: 10.1111/iju.15566.
    PubMed    
    
    
    
78. MIURA H, Hatakeyama S, Tabata R, Fujimori D, et al
    Treatment trends in patients with de novo metastatic prostate cancer in the era of upfront combination therapy.
    Int J Urol. 2024 Aug 23. doi: 10.1111/iju.15550.
    PubMed     Abstract available
    
    
    
79. MADENDERE S, Kilic M, Gurses B, Vural M, et al
    Can the Briganti 2019 nomogram be modified to predict lymph node metastasis risk in patients with prostate cancer detected with in-bore biopsy?
    Int J Urol. 2024 Aug 14. doi: 10.1111/iju.15553.
    PubMed     Abstract available
    
    
    
80. GOTO Y
    Editorial Comment on Japanese clinical practice guidelines for prostate cancer 2023.
    Int J Urol. 2024 Aug 14. doi: 10.1111/iju.15562.
    PubMed    
    
    
    
81. URABE F, Kimura S, Tashiro K
    Is meta-analysis effective in evaluating local treatment benefits for oligometastatic prostate cancer?
    Int J Urol. 2024 Aug 1. doi: 10.1111/iju.15555.
    PubMed    
    
    
    
82. TOHI Y, Osaki Y, Kato T, Honda T, et al
    Impact of the coronavirus disease pandemic on robot-assisted radical prostatectomy and urologists' treatment behaviors: A single tertiary center retrospective study.
    Int J Urol. 2024;31:899-905.
    PubMed     Abstract available
    
    
    July 2024
83. KOHJIMOTO Y, Uemura H, Yoshida M, Hinotsu S, et al
    Japanese clinical practice guidelines for prostate cancer 2023.
    Int J Urol. 2024 Jul 30. doi: 10.1111/iju.15545.
    PubMed     Abstract available
    
    
    
84. URABE F, Muramoto K, Yanagisawa T, Fukuokaya W, et al
    Changes in the treatment landscape of metastatic hormone-sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: A multicenter study.
    Int J Urol. 2024 Jul 19. doi: 10.1111/iju.15546.
    PubMed     Abstract available
    
    
    
85. AIZAWA R, Ishikawa H, Kato M, Shimizu S, et al
    Significance of androgen-deprivation therapy for intermediate- and high-risk prostate cancer treated with high-dose radiotherapy: A literature review.
    Int J Urol. 2024 Jul 17. doi: 10.1111/iju.15535.
    PubMed     Abstract available
    
    
    
86. SUN Q, Du K, Sun S, Liu Y, et al
    Local treatment benefits patients with oligometastatic prostate cancer: A systematic review and meta-analysis.
    Int J Urol. 2024 Jul 16. doi: 10.1111/iju.15540.
    PubMed     Abstract available
    
    
    
87. DELLA CORTE M, Checcucci E
    Editorial Comment on "The role of lipidic balance on erectile dysfunction in prostate cancer patients undergoing robotic surgery".
    Int J Urol. 2024 Jul 9. doi: 10.1111/iju.15543.
    PubMed    
    
    
    
88. DI BELLO F, Fraia A, Pezone G, Colla Ruvolo C, et al
    The role of lipidic balance on erectile dysfunction in prostate cancer patients undergoing robotic surgery.
    Int J Urol. 2024 Jul 3. doi: 10.1111/iju.15516.
    PubMed     Abstract available
    
    
    June 2024
89. SAITO K, Kohada Y, Hieda K, Shikuma H, et al
    Preoperative high serum total testosterone levels predict preserved postoperative sexual function in patients after nerve-sparing robot-assisted radical prostatectomy.
    Int J Urol. 2024 Jun 7. doi: 10.1111/iju.15511.
    PubMed     Abstract available
    
    
    
90. TANABE K, Kobayashi S, Tamiya T, Konishi T, et al
    Risk factors for the long-term persistent genitourinary toxicity after stereotactic body radiation therapy for localized prostate cancer: A single-center, retrospective study of 306 patients.
    Int J Urol. 2024 Jun 1. doi: 10.1111/iju.15507.
    PubMed     Abstract available
    
    
    
91. HASHIMOTO K, Kosaka T, Terada N, Kimura T, et al
    Current issues and management consensus of advanced prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference-JAPAN 2023.
    Int J Urol. 2024 Jun 1. doi: 10.1111/iju.15499.
    PubMed     Abstract available
    
    
    
92. KATO M, Shiota M, Kimura T, Hanazawa R, et al
    Validation study on the 2 mm diameter cutoff in lymph node-positive cases following radical prostatectomy in accordance with the AJCC/UICC TNM 8th edition: Real-world data analysis from a Japanese cohort.
    Int J Urol. 2024;31:662-669.
    PubMed     Abstract available
    
    
    May 2024
93. WATANABE H, Nakane K, Takahara K, Naiki T, et al
    Prognostic outcomes in Japanese patients with metastatic castration-sensitive prostate cancer: Comparative assessments between conventional androgen deprivation therapy (ADT) and ADT with novel androgen receptor signal inhibitor.
    Int J Urol. 2024 May 19. doi: 10.1111/iju.15498.
    PubMed     Abstract available
    
    
    
94. URABE F
    The relevance of circRNAs in serum of patients undergoing prostate biopsy.
    Int J Urol. 2024;31:581.
    PubMed    
    
    
    
95. SAMIRAE L, Krausewitz P, Alajati A, Kristiansen G, et al
    The relevance of circRNAs in serum of patients undergoing prostate biopsy.
    Int J Urol. 2024;31:578-580.
    PubMed    
    
    
    
96. CHIARELLI G, Davis M, Stephens A, Cirulli GO, et al
    Comparison of patient background between a real-world North American cohort and the Goteborg-2 trial.
    Int J Urol. 2024;31:562-567.
    PubMed     Abstract available
    
    
    
97. ANDO S, Sugihara T, Hinotsu S, Kishino H, et al
    Early recovery of urinary continence after robot-assisted radical prostatectomy is associated with membranous urethra and neurovascular bundle preservation.
    Int J Urol. 2024;31:492-499.
    PubMed     Abstract available
    
    
    April 2024
98. YAMAMOTO Y, Nonomura N
    Editorial Comment to Survival beyond cabazitaxel for metastatic castration-resistant prostate cancer.
    Int J Urol. 2024 Apr 4. doi: 10.1111/iju.15458.
    PubMed    
    
    
    
99. BLAS L, Shiota M, Tanegashima T, Tsukahara S, et al
    Validation of schedules for optimal prostate-specific antigen monitoring after radical prostatectomy.
    Int J Urol. 2024;31:404-408.
    PubMed     Abstract available
    
    
    March 2024
100. URABE F, Sumiyoshi T, Tashiro K, Goto T, et al
     Prostate cancer and liquid biopsies: Clinical applications and challenges.
     Int J Urol. 2024 Mar 29. doi: 10.1111/iju.15441.
     PubMed     Abstract available
     
     
     
101. GOTO Y
     Editorial Comment on Prostate cancer and liquid biopsies: Clinical applications and challenges.
     Int J Urol. 2024 Mar 29. doi: 10.1111/iju.15456.
     PubMed    
     
     
     
102. KOBAYASHI M, Matsuoka Y, Uehara S, Tanaka H, et al
     Utility of positive core number on MRI-ultrasound fusion targeted biopsy in combination with PI-RADS scores for predicting unexpected extracapsular extension of clinically localized prostate cancer.
     Int J Urol. 2024 Mar 12. doi: 10.1111/iju.15451.
     PubMed     Abstract available
     
     
     
103. GOTO Y
     Editorial Comment on Exploring androgen receptor signaling pathway in prostate cancer: A path to new discoveries.
     Int J Urol. 2024 Mar 8. doi: 10.1111/iju.15444.
     PubMed    
     
     
     
104. KAWASE M, Kato D, Tobisawa Y, Iinuma K, et al
     Efficacy and safety of combination neoadjuvant chemo-hormonal therapy and robot-assisted radical prostatectomy for oligometastatic prostate cancer.
     Int J Urol. 2024 Mar 7. doi: 10.1111/iju.15448.
     PubMed    
     
     
     
105. BLAS L, Shiota M, Tanegashima T, Kobayashi S, et al
     Survival beyond cabazitaxel for metastatic castration-resistant prostate cancer.
     Int J Urol. 2024 Mar 5. doi: 10.1111/iju.15449.
     PubMed    
     
     
     February 2024
106. PARK SJ, Park YJ, Park SM
     Response to comment: Revisiting the impact of antibiotics on prostate cancer risk: Beyond the gut microbiota.
     Int J Urol. 2024 Feb 15. doi: 10.1111/iju.15431.
     PubMed    
     
     
     
107. OBINATA D, Takayama K, Inoue S, Takahashi S, et al
     Exploring androgen receptor signaling pathway in prostate cancer: A path to new discoveries.
     Int J Urol. 2024 Feb 12. doi: 10.1111/iju.15424.
     PubMed     Abstract available
     
     
     
108. ASAI S, Kobayashi M, Fukuda S, Kimura K, et al
     Significance of atypical nodules upgraded to category 3 in Prostate Imaging Reporting and Data System version 2.1 for prostate cancer diagnosis.
     Int J Urol. 2024 Feb 12. doi: 10.1111/iju.15421.
     PubMed    
     
     
     
109. HIYAMA Y
     Editorial Comment: Proctoscopy following transrectal prostate biopsy can control rectal bleeding after prostate biopsy.
     Int J Urol. 2024;31:143.
     PubMed    
     
     
     January 2024
110. SHOJI S
     Editorial Comment to Histological parameters and stromal desmoplastic status affecting accurate diagnosis of extraprostatic extension of prostate cancer using multi-parametric magnetic resonance imaging.
     Int J Urol. 2024 Jan 29. doi: 10.1111/iju.15406.
     PubMed    
     
     
     
111. LIN YH, Chen YT, Tsai HY
     Revisiting the impact of antibiotics on prostate cancer risk: Beyond the gut microbiota.
     Int J Urol. 2024 Jan 29. doi: 10.1111/iju.15401.
     PubMed    
     
     
     
112. MORI K
     Editorial Comment from Dr Mori to Association between antibiotic use and subsequent risk of prostate cancer: A retrospective cohort study in South Korea.
     Int J Urol. 2024 Jan 24. doi: 10.1111/iju.15402.
     PubMed    
     
     
     
113. HATANO K
     Editorial Comment on "Association between antibiotic use and subsequent risk of prostate cancer: A retrospective cohort study in South Korea".
     Int J Urol. 2024 Jan 12. doi: 10.1111/iju.15393.
     PubMed    
     
     
     
114. UKIMURA O
     Editorial Comment on Does intensity-modulated radiation therapy by helical tomotherapy for prostate cancer increase the subsequent risk of bladder cancer? A propensity score-matched analysis.
     Int J Urol. 2024 Jan 10. doi: 10.1111/iju.15392.
     PubMed    
     
     
     
115. TSUKUDA F, Tanaka Y, Narita S, Shimizu T, et al
     Does intensity-modulated radiation therapy by helical tomotherapy for prostate cancer increase the subsequent risk of bladder cancer? A propensity score-matched analysis.
     Int J Urol. 2024 Jan 9. doi: 10.1111/iju.15373.
     PubMed     Abstract available
     
     
     
116. OKIHARA K, Ueda T, Fujihara A, Shiraishi T, et al
     Novel image-guided marker aimed at organ-preserving therapies for prostate cancer.
     Int J Urol. 2024 Jan 9. doi: 10.1111/iju.15389.
     PubMed     Abstract available
     
     
     
117. OKANO K, Miyai K, Mikoshi A, Edo H, et al
     Histological parameters and stromal desmoplastic status affecting accurate diagnosis of extraprostatic extension of prostate cancer using multi-parametric magnetic resonance imaging.
     Int J Urol. 2024 Jan 9. doi: 10.1111/iju.15385.
     PubMed     Abstract available
     
     
     
118. DE VELASCO MA, Kura Y, Fujita K, Uemura H, et al
     Moving toward improved immune checkpoint immunotherapy for advanced prostate cancer.
     Int J Urol. 2024 Jan 2. doi: 10.1111/iju.15378.
     PubMed     Abstract available
     
     
     
119. NAITO Y, Kato M, Nagayama J, Sano Y, et al
     Recent insights on the clinical, pathological, and molecular features of intraductal carcinoma of the prostate.
     Int J Urol. 2024;31:7-16.
     PubMed     Abstract available
     
     
     December 2023
120. YOKOMIZO A, Shiota M, Morokuma F, Eto M, et al
     GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone-sensitive prostate cancer; KYUCOG-1401.
     Int J Urol. 2023 Dec 26. doi: 10.1111/iju.15371.
     PubMed     Abstract available
     
     
     
121. PARK SJ, Hong J, Park YJ, Jeong S, et al
     Association between antibiotic use and subsequent risk of prostate cancer: A retrospective cohort study in South Korea.
     Int J Urol. 2023 Dec 21. doi: 10.1111/iju.15364.
     PubMed     Abstract available
     
     
     
122. NAKAZONO M, Urabe F, Iwatani K, Imai Y, et al
     Patients with PSA below 0.2 ng/mL at 8 years post high-dose-rate brachytherapy have an extremely low risk of subsequent recurrence.
     Int J Urol. 2023;30:1147-1154.
     PubMed     Abstract available
     
     
     November 2023
123. YUASA T
     Editorial Comment to Bone-modifying agents are protective for symptomatic skeletal events in radium-223 treatment.
     Int J Urol. 2023;30:1034-1035.
     PubMed    
     
     
     
124. SHIRAISHI K
     Evaluation of sexual function after robot-assisted radical prostatectomy: A farewell to IIEF questionnaire.
     Int J Urol. 2023;30:959-967.
     PubMed     Abstract available
     
     
     
125. BLAS L, Shiota M, Matsumoto T, Hori Y, et al
     Bone-modifying agents are protective for symptomatic skeletal events in Radium-223 treatment.
     Int J Urol. 2023;30:1029-1034.
     PubMed     Abstract available
     
     
     
126. KOHADA Y, Hieda K, Miyamoto S, Tasaka R, et al
     Retrospective evaluation of the improvement in the urinary status-related quality of life after robot-assisted radical prostatectomy.
     Int J Urol. 2023;30:1020-1027.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.